Age: 43.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Alopecia, Autoimmune thyroiditis, Hair disorder, Immunisation, Skin disorder
Clinical narrative: flare up of hashimotos hypothyroid/skin and hair issues; flare up of hashimotos hypothyroid/skin and hair issues; disrupted menstrual cycle; Significant and rapid hair loss/hair thinning; Heavy menstrual period; Longer than usual menstrual period; Chills; fever/low grade fever; Head ache; Body ache; fatigue; Swelling at injection site; Redness at injection site; Pain at injection site; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non-HCP). The reporter is the patient.  A 43-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 19Apr2021 16:00 (Lot number: ER8737) at the age of 43 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Hashimoto's Thyroid" (unspecified if ongoing), notes: Verbatim: Hashimoto's Thyroid; "Known allergies: Penicillin" (unspecified if ongoing); "Known allergies: Pertussis vaccine" (unspecified if ongoing). Concomitant medication(s) included: LEVOTHYROXINE; AMBIEN; VITAMIN D [VITAMIN D NOS]. Vaccination history included: Bnt162b2 (Dose number=1, Lot Number: ER8732, Vaccine Administration time: 04:00 PM, Previous dose Vaccine location= Left arm), administration date: 29Mar2021, when the patient was 43 years old, for Covid-19 immunization. Prior to vaccination the patient had not received any vaccines within 4 weeks and was not diagnosed with COVID-19. The following information was reported: AUTOIMMUNE THYROIDITIS (medically significant), CONDITION AGGRAVATED (medically significant) all with onset 07Jun2021, outcome "not recovered" and all described as "flare up of hashimotos hypothyroid/skin and hair issues"; CHILLS (non-serious) with onset 20Apr2021 16:00, outcome "not recovered", described as "Chills"; PYREXIA (non-serious) with onset 20Apr2021 16:00, outcome "not recovered", described as "fever/low grade fever"; HEADACHE (non-serious) with onset 20Apr2021 16:00, outcome "not recovered", described as "Head ache"; PAIN (non-serious) with onset 20Apr2021 16:00, outcome "not recovered", described as "Body ache"; FATIGUE (non-serious) with onset 20Apr2021 16:00, outcome "not recovered", described as "fatigue"; VACCINATION SITE SWELLING (non-serious) with onset 20Apr2021 16:00, outcome "not recovered", described as "Swelling at injection site"; VACCINATION SITE ERYTHEMA (non-serious) with onset 20Apr2021 16:00, outcome "not recovered", described as "Redness at injection site"; VACCINATION SITE PAIN (non-serious) with onset 20Apr2021 16:00, outcome "not recovered", described as "Pain at injection site"; HEAVY MENSTRUAL BLEEDING (non-serious) with onset 03May2021 16:00, outcome "not recovered", described as "Heavy menstrual period"; OLIGOMENORRHOEA (non-serious) with onset 03May2021 16:00, outcome "not recovered", described as "Longer than usual menstrual period"; MENSTRUAL DISORDER (non-serious) with onset 10May2021 16:00, outcome "not recovered", described as "disrupted menstrual cycle"; ALOPECIA (non-serious) with onset 10May2021 16:00, outcome "not recovered", described as "Significant and rapid hair loss/hair thinning." The events "flare up of hashimotos hypothyroid/skin and hair issues", "flare up of hashimotos hypothyroid/skin and hair issues", "chills", "fever/low grade fever", "head ache", "body ache", "fatigue", "swelling at injection site", "redness at injection site", "pain at injection site", "heavy menstrual period", "longer than usual menstrual period", "disrupted menstrual cycle", "significant and rapid hair loss/hair thinning" were evaluated at the physician office visit. The patient reported that within 3 to 6 weeks after vaccination, she experienced a disrupted menstrual cycle; significant and rapid hair loss. This occurred after the second dose and lasted 6 months. The patient's hair was starting to regrow and then after booster began to fall out again. The patient never had hair loss; it was sudden and significant and resulted in a thinning across the scalp, particularly in the top of the head and temple area; she estimated a 1/4 reduction in the volume of the area. She also experienced flare up of Hashimoto's hypothyroid including skin and hair issues at that time; further reporting she had been stable with medication for more than 5 years prior. The patient underwent the following laboratory tests and procedures: body temperature: (20Apr2021) low grade. Therapeutic measures were taken as a result of autoimmune thyroiditis, condition aggravated. Since vaccination the patient had not been tested for COVID. No follow-up attempts are possible. No further information is expected.